Abbott Nutrition. Attractive Profile and Compelling Growth Opportunities

Transcription

1 Attractive Profile and Compelling Growth Opportunities

2 Forward-Looking Statement Some statements in this presentation may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of Abbott cautions that these forwardlooking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott s operations are discussed in Item 1A, Risk Factors, to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2013, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. 2 Page 2

3 Large Markets and Favorable Trends Large and growing markets Favorable demographics and economics Rapidly expanding aging population globally 2013 Abbott Relevant Nutrition Market High birth rates in emerging markets Increasing socio-economic status in emerging markets Growing awareness of the role of nutrition for health and wellness Pediatric $26Bn Adult $4Bn Sources: Euromonitor, Nielsen, IMS and company estimates. 3 Page 3

4 #1 Nutrition Company Worldwide Pediatric Nutrition #1 in the U.S. Adult Nutrition #1 in the U.S. #1 worldwide Global Nutrition #1 or #2 in 25 countries 50 consumer brands; 100 countries #1 based on the adult and pediatric markets in which Abbott competes 4 Page 4

5 Unique Balance across Geographies and Portfolio Geographic Balance Portfolio Balance Sales Sales 45% US 55% OUS 55% Pediatric 45% Adult Rounded Sales Mix in Full Year Page 5

6 Growth Strategies Strengthen Portfolio with steady rhythm of science-based new products Expand Footprint in key high-growth emerging markets Grow, shape, and further penetrate the adult nutrition market Expand Operating Margins to fund investments in growth 6 Page 6

7 Leading with Science Strong investment in R&D; part of our heritage R&D Productivity New product launches Clinical trials & patent applications Singapore Localized R&D capabilities Expanding our footprint and capabilities New facilities in or near priority emerging markets Partnerships to leverage external expertise 7 Page 7

8 Science-Based Benefit Platforms Tolerance Cognition Immunity Sensitivity Comfort GI Health Early Development Learning & Memory Resistance Allergies Lean Body Mass Muscle & Bone Recovery Caloric Density Epigentics Diabetes Metabolism Inflammation Inflammatory Disease Processes 8 Page 8

9 Pediatric Nutrition Science-based, Differentiated Portfolio MATERNAL INFANT UP-AGE SPECIALTY Combination Prime Nutrition 9 Page 9

10 Growth Strategies Strengthen Portfolio with steady rhythm of science-based new products Expand Footprint in key high-growth emerging markets Grow, shape, and further penetrate the adult nutrition market Expand Operating Margins to fund investments in growth 10 Page 10

11 Pediatric Nutrition Focused on Key Priority Emerging Markets China India Brazil Russia Vietnam Mexico Turkey 11 Page 11

12 Growth Strategies Strengthen Portfolio with steady rhythm of science-based new products Expand Footprint in key high-growth emerging markets Grow, shape, and further penetrate the adult nutrition market Expand Operating Margins to fund investments in growth 12 Page 12

13 Adult Nutrition Favorable Demographics Population Age 50+ years old (key markets; in millions) % of Total Population (key markets) % 40% China India United States Brazil Mexico Vietnam UK Indonesia Japan Source: United Nations, Department of Economic and Social Affairs, Population Division (2011). World Population Prospects: The 2010 Revision, CD-ROM Edition. 13 Page 13

14 Adult Nutrition Innovation to meet local market and clinical needs Category Creation Innovation Global Expansion Local Solutions Ensure 1973 Ensure Today 14 Page 14

15 Adult Nutrition Broad Portfolio for Recovery and Healthy Aging Most Sick & Compromised Well and Healthy Aging Acute Care Hospital Recovery/LTC Disease-Specific Healthy Aging Diabetes Kidney Disease Oncology 15 Page 15

16 Adult Nutrition Lean Body Mass loss in Aging and Recovery Average muscle-mass loss with age Lean Body Mass loss in Bed Rest 1 0 Hospitalized Older Patients Change (Kg) -0.5 ~1 kg (>2lbs) -1.0 More than 2 lbs in just 3 days 1 Paddon-Jones, Abbott Nutrition Research Conference: Selected Summaries. The Role of Nutrition in Accretion, Retention and Recovery of Lean Body Mass, from 2009: Page 16

17 Adult Nutrition Potential to Improve Health Economic Outcomes HEOR Study Impact of Oral Nutritional Supplementation on Hospital Outcomes Published in American Journal of Managed Care 44 million hospital episodes across the US over 11 years Length of Stay Episode Cost 30 Day Readmission Rate 21% 21.6% 6.7% Source: Philipson, T.J., et al., Impact of Oral Nutritional Supplementation on Hospital Outcomes. Am J Managed Care. 2013;19:(2): Page 17

18 Growth Strategies Strengthen Portfolio with steady rhythm of science-based new products Expand Footprint in key high-growth emerging markets Grow, shape, and further penetrate the adult nutrition market Expand Operating Margins to fund investments in growth 18 Page 18

19 Significantly Expand Operating Margin Nutrition Operating Margin: Targeting >700 basis points of expansion Margin Improvement Initiatives >20% of sales 18.7% of sales 15.8% of sales 13.2% of sales Product Materials & Packaging Manufacturing Processes & Plant Locations Supply Chain & Distribution Product & Market Rationalization Page 19

20 Unprecedented Capacity Expansion in 2014 Meeting Demand and Enhancing Profitability Jiaxing, China Tipp City, Ohio Gujarat, India Powder Facility Aseptic Liquid Facility Powder Facility 20 Page 20

21 Delivering Against our Key Growth Drivers Balanced Portfolio Leadership Innovation Emerging Markets Margin Expansion 55% Pediatric 45% Adult 55% OUS #1 US Pediatric #1 Adult #1 or 2 in 25 countries ~70 product launches in 2013 Scientific heritage 45% of Sales Building portfolio, presence, capabilities +550 bps since 2011 >20% operating margin by % US 6 key benefit platforms 21 Page 21

22